Navigation Links
Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
Date:2/14/2008

CHESHIRE, Conn., Feb. 14 /PRNewswire-FirstCall/ -- The Oklahoma Medical Research Foundation ("OMRF") and Alexion Pharmaceuticals, Inc. ("Alexion," Nasdaq: ALXN) today announced that Alexion has agreed to acquire from OMRF all rights to certain patents related to complement-inhibition technology.

Background

The patents cover inventions made by OMRF in the 1980s relating to the treatment of complement system mediated disorders, to which Alexion has had limited rights as a licensee since the inception of the company. In the 1990s, Alexion began programs to create and develop monoclonal antibodies capable of blocking the body's complement system. One result of these Alexion programs was the development of Soliris(R), which was approved for marketing by the U.S. Food and Drug Administration and by the European Commission during 2007. Soliris(R) (eculizumab) is a complement inhibitor product developed and marketed by Alexion for the treatment of paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening disease.

"Soliris opened a major new therapeutic avenue for patients with PNH, and the scientists at Alexion had to overcome tremendous obstacles to make this treatment a reality," said OMRF President Stephen Prescott, M.D. "I am proud that Peter Sims, M.D., Ph.D., and Therese Wiedmer, Ph.D., while working as scientists at OMRF and in their subsequent careers, had the opportunity to contribute to bringing this much-needed treatment to patients suffering from a life-threatening disease."

"Complex scientific breakthroughs are often built by combining research advances from different sources," said David Keiser, President and Chief Operating Officer of Alexion. "OMRF is widely respected for its technological accomplishments, and we thank the OMRF team for its contributions to the development of our anti-complement technology."

Under an agreement recently executed by the two organizations, Alexion will pay OMRF $10 million to acquire all rights and interests to the patents, in various amounts to be remitted in 2008 and the first half of 2009. No further amounts, including royalties, will be owed to OMRF in respect of sales of Soliris or other use of the OMRF patents. Accordingly, the previously announced claims filed by OMRF and counterclaims filed by Alexion in the U.S. District Court for the Northern District of Oklahoma will be dismissed.

About OMRF and Alexion

Chartered in 1946, OMRF (http://www.omrf.org) is a nonprofit biomedical research institute that focuses its research on cardiovascular disease, Alzheimer's, lupus and cancer. For more information, please contact Adam Cohen (adam- cohen@omrf.org) at the Oklahoma Medical Research Foundation, (405) 271-7159.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. Alexion is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is pursuing development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: http://www.alexionpharm.com.

[ALXN-G]

Contact: Alexion Pharmaceuticals, Inc.

Irving Adler

Sr. Director, Corporate Communications

203-272-2596

Makovsky & Company

Mark Marmur (Media)

212-508-9670

Rx Communications

Rhonda Chiger (Investors)

917-322-2569


'/>"/>
SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
2. Alexion to Present at Bear Stearns Healthcare Conference
3. Linc Facility Services Acquires Morse Medical
4. Acrongenomics Acquires Equity Stake in Molecular Vision
5. Inverness Medical Innovations Acquires ParadigmHealth
6. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
7. Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack
8. Raptor Pharmaceuticals Acquires Orphan Clinical Program
9. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
10. Neogen Acquires Assets of Rivard Instruments
11. Advanced Instruments Acquires Mart Microbiology B.V.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... SAN DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... website as part of its corporate rebranding initiative announced today. The bold new ... broaden its reach, as the company moves into a significant growth period. , It ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program ... in Volunteer Experience from US2020. , US2020’s mission is to change the trajectory ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):